Telehealth for patients with interstitial lung diseases (ILD): Results of an international survey of clinicians

Malik Althobiani; Jaber S. Alqahtani; John R. Hurst; Anne Marie Russell; Joanna Porter

doi:10.1136/bmjresp-2021-001088

Telehealth for patients with interstitial lung diseases (ILD): Results of an international survey of clinicians

Malik Althobiani, Jaber S. Alqahtani, John R. Hurst, Anne Marie Russell, Joanna Porter^*

^*Corresponding author for this work

Nursing and Midwifery

Research output: Contribution to journal › Article › peer-review

25 Downloads (Pure)

Abstract

Introduction: Clinicians and policymakers are promoting widespread use of home technology including spirometry to detect disease progression for patients with interstitial lung disease (ILD); the COVID-19 pandemic has accelerated this. Data collating clinicians' views on the potential utility of telehealth in ILD are limited.

Aim: This survey investigated clinicians' opinions about contemporary methods and practices used to monitor disease progression in patients with ILD using telehealth.

Methods: Clinicians were invited to participate in a cross-sectional survey (SurveyMonkey) of 13 questions designed by an expert panel. Telehealth was defined as home monitoring of symptoms and physiological parameters with regular automatic transmission of data from the patient's home to the clinician. Data are presented as percentages of respondents.

Results: A total of 207 clinicians from 23 countries participated in the survey. A minority (81, 39%) reported using telehealth. 50% (n=41) of these respondents completed a further question about the effectiveness of telehealth. A majority of respondents (32, 70%) rated it to be quite or more effective than face-to-face visit. There were a greater number of respondents using telehealth from Europe (94, 45%) than Asia (51, 25%) and America (24%). Clinicians reported the most useful telehealth monitoring technologies as smartphone apps (59%) and wearable sensors (30%). Telehealth was most frequently used for monitoring disease progression (70%), quality of life (63%), medication use (63%) and reducing the need for in-person visits (63%). Clinicians most often monitored symptoms (93%), oxygen saturation (74%) and physical activity (72%). The equipment perceived to be most effective were spirometers (43%) and pulse oximeters (33%). The primary barriers to clinicians' participation in telehealth were organisational structure (80%), technical challenges (63%) and lack of time and/or workload (63%). Clinicians considered patients' barriers to participation might include lack of awareness (76%), lack of knowledge using smartphones (60%) and lack of confidence in telehealth (56%).

Conclusion:G

Original language	English
Article number	e001088
Number of pages	8
Journal	BMJ Open Respiratory Research
Volume	8
Issue number	1
DOIs	https://doi.org/10.1136/bmjresp-2021-001088
Publication status	Published - 30 Dec 2021

Bibliographical note

Funding Information:
Contributors MA, JRH, JP, A-MR: conception, design, distributed the survey, data acquisition, analysis, interpretation and approval of final version. MA contributed conceptualisation, distributed the survey, data collection, formal analysis, project administration, wrote original draft, reviewed and edited the manuscript; JSA reviewed and edited the manuscript. MA, JRH, JP, A-MR are guarantors Funding This work was supported by Department of Respiratory Therapy, Faculty of Medical Rehabilitation Sciences, King Abdulaziz University, Jeddah, Saudi Arabia through the Saudi Arabian Cultural Bureau in London.

Publisher Copyright:
©

Keywords

interstitial fibrosis
sarcoidosis

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1136/bmjresp-2021-001088Licence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

AlthobianiM2021TelehealthFinal published version, 623 KBLicence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

Cite this

@article{a772ad8e3fc34c7884dfc938985eddca,

title = "Telehealth for patients with interstitial lung diseases (ILD): Results of an international survey of clinicians",

abstract = "Introduction: Clinicians and policymakers are promoting widespread use of home technology including spirometry to detect disease progression for patients with interstitial lung disease (ILD); the COVID-19 pandemic has accelerated this. Data collating clinicians' views on the potential utility of telehealth in ILD are limited. Aim: This survey investigated clinicians' opinions about contemporary methods and practices used to monitor disease progression in patients with ILD using telehealth. Methods: Clinicians were invited to participate in a cross-sectional survey (SurveyMonkey) of 13 questions designed by an expert panel. Telehealth was defined as home monitoring of symptoms and physiological parameters with regular automatic transmission of data from the patient's home to the clinician. Data are presented as percentages of respondents. Results: A total of 207 clinicians from 23 countries participated in the survey. A minority (81, 39%) reported using telehealth. 50% (n=41) of these respondents completed a further question about the effectiveness of telehealth. A majority of respondents (32, 70%) rated it to be quite or more effective than face-to-face visit. There were a greater number of respondents using telehealth from Europe (94, 45%) than Asia (51, 25%) and America (24%). Clinicians reported the most useful telehealth monitoring technologies as smartphone apps (59%) and wearable sensors (30%). Telehealth was most frequently used for monitoring disease progression (70%), quality of life (63%), medication use (63%) and reducing the need for in-person visits (63%). Clinicians most often monitored symptoms (93%), oxygen saturation (74%) and physical activity (72%). The equipment perceived to be most effective were spirometers (43%) and pulse oximeters (33%). The primary barriers to clinicians' participation in telehealth were organisational structure (80%), technical challenges (63%) and lack of time and/or workload (63%). Clinicians considered patients' barriers to participation might include lack of awareness (76%), lack of knowledge using smartphones (60%) and lack of confidence in telehealth (56%). Conclusion:G",

keywords = "interstitial fibrosis, sarcoidosis",

author = "Malik Althobiani and Alqahtani, {Jaber S.} and Hurst, {John R.} and Russell, {Anne Marie} and Joanna Porter",

note = "Funding Information: Contributors MA, JRH, JP, A-MR: conception, design, distributed the survey, data acquisition, analysis, interpretation and approval of final version. MA contributed conceptualisation, distributed the survey, data collection, formal analysis, project administration, wrote original draft, reviewed and edited the manuscript; JSA reviewed and edited the manuscript. MA, JRH, JP, A-MR are guarantors Funding This work was supported by Department of Respiratory Therapy, Faculty of Medical Rehabilitation Sciences, King Abdulaziz University, Jeddah, Saudi Arabia through the Saudi Arabian Cultural Bureau in London. Publisher Copyright: {\textcopyright} ",

year = "2021",

month = dec,

day = "30",

doi = "10.1136/bmjresp-2021-001088",

language = "English",

volume = "8",

journal = "BMJ Open Respiratory Research",

issn = "2052-4439",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - Telehealth for patients with interstitial lung diseases (ILD)

T2 - Results of an international survey of clinicians

AU - Althobiani, Malik

AU - Alqahtani, Jaber S.

AU - Hurst, John R.

AU - Russell, Anne Marie

AU - Porter, Joanna

N1 - Funding Information: Contributors MA, JRH, JP, A-MR: conception, design, distributed the survey, data acquisition, analysis, interpretation and approval of final version. MA contributed conceptualisation, distributed the survey, data collection, formal analysis, project administration, wrote original draft, reviewed and edited the manuscript; JSA reviewed and edited the manuscript. MA, JRH, JP, A-MR are guarantors Funding This work was supported by Department of Respiratory Therapy, Faculty of Medical Rehabilitation Sciences, King Abdulaziz University, Jeddah, Saudi Arabia through the Saudi Arabian Cultural Bureau in London. Publisher Copyright: ©

PY - 2021/12/30

Y1 - 2021/12/30

N2 - Introduction: Clinicians and policymakers are promoting widespread use of home technology including spirometry to detect disease progression for patients with interstitial lung disease (ILD); the COVID-19 pandemic has accelerated this. Data collating clinicians' views on the potential utility of telehealth in ILD are limited. Aim: This survey investigated clinicians' opinions about contemporary methods and practices used to monitor disease progression in patients with ILD using telehealth. Methods: Clinicians were invited to participate in a cross-sectional survey (SurveyMonkey) of 13 questions designed by an expert panel. Telehealth was defined as home monitoring of symptoms and physiological parameters with regular automatic transmission of data from the patient's home to the clinician. Data are presented as percentages of respondents. Results: A total of 207 clinicians from 23 countries participated in the survey. A minority (81, 39%) reported using telehealth. 50% (n=41) of these respondents completed a further question about the effectiveness of telehealth. A majority of respondents (32, 70%) rated it to be quite or more effective than face-to-face visit. There were a greater number of respondents using telehealth from Europe (94, 45%) than Asia (51, 25%) and America (24%). Clinicians reported the most useful telehealth monitoring technologies as smartphone apps (59%) and wearable sensors (30%). Telehealth was most frequently used for monitoring disease progression (70%), quality of life (63%), medication use (63%) and reducing the need for in-person visits (63%). Clinicians most often monitored symptoms (93%), oxygen saturation (74%) and physical activity (72%). The equipment perceived to be most effective were spirometers (43%) and pulse oximeters (33%). The primary barriers to clinicians' participation in telehealth were organisational structure (80%), technical challenges (63%) and lack of time and/or workload (63%). Clinicians considered patients' barriers to participation might include lack of awareness (76%), lack of knowledge using smartphones (60%) and lack of confidence in telehealth (56%). Conclusion:G

AB - Introduction: Clinicians and policymakers are promoting widespread use of home technology including spirometry to detect disease progression for patients with interstitial lung disease (ILD); the COVID-19 pandemic has accelerated this. Data collating clinicians' views on the potential utility of telehealth in ILD are limited. Aim: This survey investigated clinicians' opinions about contemporary methods and practices used to monitor disease progression in patients with ILD using telehealth. Methods: Clinicians were invited to participate in a cross-sectional survey (SurveyMonkey) of 13 questions designed by an expert panel. Telehealth was defined as home monitoring of symptoms and physiological parameters with regular automatic transmission of data from the patient's home to the clinician. Data are presented as percentages of respondents. Results: A total of 207 clinicians from 23 countries participated in the survey. A minority (81, 39%) reported using telehealth. 50% (n=41) of these respondents completed a further question about the effectiveness of telehealth. A majority of respondents (32, 70%) rated it to be quite or more effective than face-to-face visit. There were a greater number of respondents using telehealth from Europe (94, 45%) than Asia (51, 25%) and America (24%). Clinicians reported the most useful telehealth monitoring technologies as smartphone apps (59%) and wearable sensors (30%). Telehealth was most frequently used for monitoring disease progression (70%), quality of life (63%), medication use (63%) and reducing the need for in-person visits (63%). Clinicians most often monitored symptoms (93%), oxygen saturation (74%) and physical activity (72%). The equipment perceived to be most effective were spirometers (43%) and pulse oximeters (33%). The primary barriers to clinicians' participation in telehealth were organisational structure (80%), technical challenges (63%) and lack of time and/or workload (63%). Clinicians considered patients' barriers to participation might include lack of awareness (76%), lack of knowledge using smartphones (60%) and lack of confidence in telehealth (56%). Conclusion:G

KW - interstitial fibrosis

KW - sarcoidosis

UR - http://www.scopus.com/inward/record.url?scp=85122623541&partnerID=8YFLogxK

U2 - 10.1136/bmjresp-2021-001088

DO - 10.1136/bmjresp-2021-001088

M3 - Article

C2 - 34969772

AN - SCOPUS:85122623541

SN - 2052-4439

VL - 8

JO - BMJ Open Respiratory Research

JF - BMJ Open Respiratory Research

IS - 1

M1 - e001088

ER -

Telehealth for patients with interstitial lung diseases (ILD): Results of an international survey of clinicians

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this